Abstract: The present disclosure provides an array substrate and a touch control display panel. The touch control display panel is provided with a pixel electrode layer disposed on a wire layer, and has a first pixel electrode, a second pixel electrode, and a third pixel electrode disposed sequentially. The first pixel electrode has at least one first slit, the second pixel electrode has at least one second slit, and the third pixel electrode has at least one third slit. A sum of width of the at least one first slit is greater than a sum of width of the at least one third slit.

Abstract: The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: Systems, methods, and non-transitory computer-readable media can determine that a user operating a computing device has accessed a content item through the social networking system. A determination is made that the content item includes at least a first section of content and a second section of content, wherein the first section of content is restricted to users that are associated with a group of users, and wherein the second section of content is available to all users. A determination is made that the user is associated with the group of users. The content item is provided for presentation through a display screen of the computing device, wherein both the first section of content and the second section of content are presented to the user.

Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Abstract: The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Abstract: Disclosed is a power system including a battery pack and a battery management system, the battery management system including a controller and a storage unit storing one or more executable programs executable to achieve battery functions.

Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Abstract: Systems, methods, and non-transitory computer-readable media can determine that a user operating a computing device has accessed a content item through the social networking system. A determination is made that the content item includes at least a first section of content and a second section of content, wherein the first section of content is restricted to users that are associated with a group of users, and wherein the second section of content is available to all users. A determination is made that the user is associated with the group of users. The content item is provided for presentation through a display screen of the computing device, wherein both the first section of content and the second section of content are presented to the user.

Abstract: The invention discloses a method of automatic management on configuration information based upon an intelligent substation, the intelligent substation applying the IEC-61850 standard including IED devices and a switch, wherein the method includes the following steps: parsing an intelligent substation configuration file to acquire communication configuration information and communication association configuration information of the IED devices; and generating a switch configuration file from the communication configuration information and the communication association configuration information of the IED devices. The invention can parse the intelligent substation configuration file, generate the switch configuration file and perform automatic configuration of the industrial Ethernet switch in the intelligent substation using the switch configuration file.

Abstract: Disclosed is a power system including a battery pack and a battery management system, the battery management system including a controller and a storage unit storing one or more executable programs executable to achieve battery functions.

Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.